CD274 and glioblastoma: Effects on the PD-1/PD-L1 axis and blocking these interactions have shown good results, reducing the number of depleted T cells in the microenvironment (which improves cytotoxic anti-tumor effects) and promoting immunological memory [48], so inhibitory therapy targeting PD-1 and PD-L1 plays an important role in current glioblastoma treatment protocols [42,49,50].